Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | TYMS | P04818 | 2/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
| ▸ | ATG7 | O95352 | 1/20 | 0.30 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401331 | 0.87 | ADRB1 (0.44) | ADRB1DNMT1 | |
| SCHEMBL500621 | 0.85 | ADRB1 (0.47) | ADRB1DNMT1 | |
| SCHEMBL2991978 | 0.84 | TYMS (0.47) | POLBTYMS | |
| Phosphoric Acid SCHEMBL6461598 | 0.81 | DNMT1 (0.44) | ADRB1DNMT1POLBTYMS | |
| Phosphoric Acid SCHEMBL3236303 | 0.81 | DNMT1 (0.44) | ADRB1DNMT1POLBTYMS | |
| SCHEMBL154965 | 0.80 | POLB (0.45) | POLBTYMSNT5E | |
| Tetrabuthylammonium SCHEMBL19462589 | 0.76 | TYMS (0.41) | POLBTYMS | |
| Tetrabuthylammonium SCHEMBL19462587 | 0.73 | ADRB1 (0.37) | ADRB1DNMT1 | |
| SCHEMBL31685173 | 0.72 | ADRB1 (0.33) | ADRB1DNMT1POLB | |
| SCHEMBL2121102 | 0.71 | TK1 (0.39) | ADRB1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716253-B2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8476416-B2 | comprises a dinucleotide analog that includes a non-naturally occurring pyrimidine base; for treating autoimmune disorders, such as autoimmune asthma; allergies | IDERA PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8030462-B2 | Immunotherapy; induce immunology response | IDERA PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-7932367-B2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2292632-A2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | Idera Pharmaceuticals, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-7833538-B2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7824696-B2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7790168-B2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080027214-A1 | Modulation of immunostimulatory activity of immunostimulatory Oligonucleotide analogs by positional chemical changes | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2008-01-31 | — | — | US | disclosed |
| EP-1322656-B1 | MODULATION OF IMMUNOSTIMULATORY ACTIVITY OF IMMUNOSTIMULATORY OLIGONUCLEOTIDE ANALOGS BY POSITIONAL CHEMICAL CHANGES | IDERA PHARMACEUTICALS INC (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070072198-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1736479-A2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | Idera Pharmaceuticals, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060142224-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2006-06-29 | — | — | US | disclosed |
| US-20060135454-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2006-06-22 | — | — | US | disclosed |
| US-20050026858-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2005-02-03 | — | — | US | disclosed |
| US-20040266709-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2004-12-30 | — | — | US | disclosed |
| US-20040266710-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2004-12-30 | — | — | US | disclosed |
| EP-1322656-A2 | MODULATION OF IMMUNOSTIMULATORY ACTIVITY OF IMMUNOSTIMULATORY OLIGONUCLEOTIDE ANALOGS BY POSITIONAL CHEMICAL CHANGES | HYBRIDON, INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020137714-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2002-09-26 | — | — | US | disclosed |
| WO-2002026757-A2 | MODULATION OF IMMUNOSTIMULATORY ACTIVITY OF IMMUNOSTIMULATORY OLIGONUCLEOTIDE ANALOGS BY POSITIONAL CHEMICAL CHANGES | HYBRIDON, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027214-A1 | Modulation of immunostimulatory activity of immunostimulatory Oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | ADRB1 2951/4885DNMT1 396/4885POLB 176/4885 |
| US-20040266709-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | ADRB1 2951/4885DNMT1 396/4885POLB 176/4885 |
| US-20020137714-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | ADRB1 2951/4885DNMT1 396/4885POLB 176/4885 |
| US-20040266710-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | ADRB1 2951/4885DNMT1 396/4885POLB 176/4885 |
| US-20060135454-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | ADRB1 2951/4885DNMT1 396/4885POLB 176/4885 |
| US-20050026858-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | ADRB1 2951/4885DNMT1 396/4885POLB 176/4885 |
| US-20060142224-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | ADRB1 2951/4885DNMT1 396/4885POLB 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.